Skip to main content
Erschienen in: Strahlentherapie und Onkologie 11/2017

19.06.2017 | Original Article

Proton therapy of iris melanoma with 50 CGE

Influence of target volume on clinical outcome

verfasst von: Aline I. Riechardt, MD, Bettina Karle, Dino Cordini, Jens Heufelder, PhD, Prof. Volker Budach, MD, PhD, Prof. Antonia M. Joussen, PhD, Johannes Gollrad, MD

Erschienen in: Strahlentherapie und Onkologie | Ausgabe 11/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The aim of this study was to evaluate local tumour control, incidence of radiation-induced glaucoma and associated interventions of sector-based and whole anterior segment proton beam therapy (PBT) for the treatment of iris melanoma.

Patients and methods

We retrospectively analysed the data of 77 patients with iris melanoma who underwent PBT applied as 50 CGE in four daily fractions. Of the patients, 47 received PBT with a circular-shaped collimator and 30 with a conformal sector-shaped target volume. Local control, eye preservation and secondary glaucoma were evaluated.

Results

Median follow-up time was 54.9 months. Local tumour control was 100% in patients receiving whole anterior segment irradiation. Two patients developed pigment dispersion in the non-irradiated area after sector-based PBT and received whole anterior segment salvage PBT. The mean volume of ciliary body irradiated was 89.0% and 34.9% for whole anterior segment and lesion-based irradiation, respectively. At the end of follow-up, secondary glaucoma was found in 74.3% of the patients with whole anterior segment irradiation and in 19.2% with sector-based irradiation. Patients with sector-based PBT had a stable visual acuity of logMAR 0.1, while it declined from logMAR 0.1 to 0.4 after whole anterior segment irradiation.

Conclusion

We found a significant reduction in radiation-induced secondary glaucoma and glaucoma-associated surgical interventions and stable visual acuity after sector-based irradiation compared with whole anterior segment irradiation. Sector-based irradiation revealed a higher risk for local recurrence, but selected patients with well-circumscribed iris melanoma benefit from applying a lesion-based target volume when treated with sector-based PBT.
Literatur
1.
Zurück zum Zitat Damato B (2000) Uveal melanoma. In: Ocular tumours: Diagnosis and treatment. Butterworth-Heimann, Oxford, pp 57–93 Damato B (2000) Uveal melanoma. In: Ocular tumours: Diagnosis and treatment. Butterworth-Heimann, Oxford, pp 57–93
3.
Zurück zum Zitat Shields CL, Shields JA, Materin M et al (2001) Iris melanoma: Risk factors for metastasis in 169 consecutive patients. Ophthalmology 108:172–178CrossRefPubMed Shields CL, Shields JA, Materin M et al (2001) Iris melanoma: Risk factors for metastasis in 169 consecutive patients. Ophthalmology 108:172–178CrossRefPubMed
4.
Zurück zum Zitat Conway RM, Chua WC, Qureshi C, Billson FA (2001) Primary iris melanoma: Diagnostic features and outcome of conservative surgical treatment. Br J Ophthalmol 85:848–854CrossRefPubMedPubMedCentral Conway RM, Chua WC, Qureshi C, Billson FA (2001) Primary iris melanoma: Diagnostic features and outcome of conservative surgical treatment. Br J Ophthalmol 85:848–854CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Naumann GO, Rummelt V (1996) Block excision of tumors of the anterior uvea: Report on 68 consecutive patients. Ophthalmology 103:2017–2027CrossRefPubMed Naumann GO, Rummelt V (1996) Block excision of tumors of the anterior uvea: Report on 68 consecutive patients. Ophthalmology 103:2017–2027CrossRefPubMed
6.
Zurück zum Zitat Shields CL, Shields JA, De Potter P et al (1995) Treatment of non-resectable malignant iris tumours with custom designed plaque radiotherapy. Br J Ophthalmol 79:306–312CrossRefPubMedPubMedCentral Shields CL, Shields JA, De Potter P et al (1995) Treatment of non-resectable malignant iris tumours with custom designed plaque radiotherapy. Br J Ophthalmol 79:306–312CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Finger PT (2001) Plaque radiation therapy for malignant melanoma of the iris and ciliary body. Am J Ophthalmol 132:328–335CrossRefPubMed Finger PT (2001) Plaque radiation therapy for malignant melanoma of the iris and ciliary body. Am J Ophthalmol 132:328–335CrossRefPubMed
8.
Zurück zum Zitat Sandinha MT, Kacperek A, Errington RD et al (2014) Recurrence of iris melanoma after proton beam therapy. Br J Ophthalmol 98:484–487CrossRefPubMed Sandinha MT, Kacperek A, Errington RD et al (2014) Recurrence of iris melanoma after proton beam therapy. Br J Ophthalmol 98:484–487CrossRefPubMed
9.
Zurück zum Zitat Konstantinidis L, Roberts D, Errington RD et al (2013) Whole anterior segment proton beam radiotherapy for diffuse iris melanoma. Br J Ophthalmol 97:471–474CrossRefPubMed Konstantinidis L, Roberts D, Errington RD et al (2013) Whole anterior segment proton beam radiotherapy for diffuse iris melanoma. Br J Ophthalmol 97:471–474CrossRefPubMed
10.
Zurück zum Zitat Damato B, Kacperek A, Chopra M et al (2005) Proton beam radiotherapy of iris melanoma. Int J Radiat Oncol Biol Phys 63:109–115CrossRefPubMed Damato B, Kacperek A, Chopra M et al (2005) Proton beam radiotherapy of iris melanoma. Int J Radiat Oncol Biol Phys 63:109–115CrossRefPubMed
11.
Zurück zum Zitat Harrabi SB, Bougatf N, Mohr A et al (2016) Dosimetric advantages of proton therapy over conventional radiotherapy with photons in young patients and adults with low-grade glioma. Strahlenther Onkol 192:759–769CrossRefPubMedPubMedCentral Harrabi SB, Bougatf N, Mohr A et al (2016) Dosimetric advantages of proton therapy over conventional radiotherapy with photons in young patients and adults with low-grade glioma. Strahlenther Onkol 192:759–769CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Gurtner K, Baumann M (2015) Proton therapy of pediatric rhabdomyosarcoma: Same tumor control as photon therapy, with less adverse effects. Strahlenther Onkol 191:814–816CrossRefPubMed Gurtner K, Baumann M (2015) Proton therapy of pediatric rhabdomyosarcoma: Same tumor control as photon therapy, with less adverse effects. Strahlenther Onkol 191:814–816CrossRefPubMed
13.
Zurück zum Zitat Hrbacek J, Mishra KK, Kacperek A et al (2016) Practice patterns analysis of ocular proton therapy centers: the international OPTIC survey. Int J Radiat Oncol Biol Phys 95:336–343CrossRefPubMed Hrbacek J, Mishra KK, Kacperek A et al (2016) Practice patterns analysis of ocular proton therapy centers: the international OPTIC survey. Int J Radiat Oncol Biol Phys 95:336–343CrossRefPubMed
14.
Zurück zum Zitat Willerding GD, Cordini D, Hackl C et al (2015) Proton beam radiotherapy of diffuse iris melanoma in 54 patients. Br J Ophthalmol 99:812–816CrossRefPubMed Willerding GD, Cordini D, Hackl C et al (2015) Proton beam radiotherapy of diffuse iris melanoma in 54 patients. Br J Ophthalmol 99:812–816CrossRefPubMed
15.
Zurück zum Zitat Sobin LH, Gospodarowicz MK, Wittekind C (2009) TNM classification of malignant tumours, 7th edn. Wiley-Blackwell, Oxford Sobin LH, Gospodarowicz MK, Wittekind C (2009) TNM classification of malignant tumours, 7th edn. Wiley-Blackwell, Oxford
16.
17.
Zurück zum Zitat Dobler B, Bendl R (2002) Precise modeling of the eye for proton therapy of intra-ocular tumours. Phys Med Biol 47:593–613CrossRefPubMed Dobler B, Bendl R (2002) Precise modeling of the eye for proton therapy of intra-ocular tumours. Phys Med Biol 47:593–613CrossRefPubMed
18.
Zurück zum Zitat Lumbroso-Le Rouic L, Delacroix S, Dendale R et al (2006) Proton beam therapy for iris melanomas. Eye 20:1300–1305CrossRefPubMed Lumbroso-Le Rouic L, Delacroix S, Dendale R et al (2006) Proton beam therapy for iris melanomas. Eye 20:1300–1305CrossRefPubMed
19.
Zurück zum Zitat Mishra KK, Daftari IK, Weinberg V et al (2013) Risk factors for neovascular glaucoma after proton beam therapy of uveal melanoma: a detailed analysis of tumor and dose-volume parameters. Int J Radiat Oncol Biol Phys 87:330–336CrossRefPubMed Mishra KK, Daftari IK, Weinberg V et al (2013) Risk factors for neovascular glaucoma after proton beam therapy of uveal melanoma: a detailed analysis of tumor and dose-volume parameters. Int J Radiat Oncol Biol Phys 87:330–336CrossRefPubMed
20.
Zurück zum Zitat Rahmi A, Mammar H, Thariat J et al (2014) Proton beam therapy for presumed and confirmed iris melanomas: a review of 36 cases. Graefes Arch Clin Exp Ophthalmol 252:1515–1521CrossRefPubMed Rahmi A, Mammar H, Thariat J et al (2014) Proton beam therapy for presumed and confirmed iris melanomas: a review of 36 cases. Graefes Arch Clin Exp Ophthalmol 252:1515–1521CrossRefPubMed
21.
Zurück zum Zitat Rundle P, Singh AD, Rennie I (2007) Proton beam therapy for iris melanoma: a review of 15 cases. Eye 21:79–82CrossRefPubMed Rundle P, Singh AD, Rennie I (2007) Proton beam therapy for iris melanoma: a review of 15 cases. Eye 21:79–82CrossRefPubMed
Metadaten
Titel
Proton therapy of iris melanoma with 50 CGE
Influence of target volume on clinical outcome
verfasst von
Aline I. Riechardt, MD
Bettina Karle
Dino Cordini
Jens Heufelder, PhD
Prof. Volker Budach, MD, PhD
Prof. Antonia M. Joussen, PhD
Johannes Gollrad, MD
Publikationsdatum
19.06.2017
Verlag
Springer Berlin Heidelberg
Erschienen in
Strahlentherapie und Onkologie / Ausgabe 11/2017
Print ISSN: 0179-7158
Elektronische ISSN: 1439-099X
DOI
https://doi.org/10.1007/s00066-017-1166-1

Weitere Artikel der Ausgabe 11/2017

Strahlentherapie und Onkologie 11/2017 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.